Price
Financials
Consolidated, Rs crore| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 |
| Profit before tax | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Tax % | 25% | 26% | -25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS in Rs | 2.59 | 4.24 | 2.90 | 4.00 | 4.75 | 4.92 | 3.45 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,250 |
| Expenses | 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,559 | 1,592 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 634 | 658 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 29% | 29% |
| Other Income | 6 | 18 | 27 | 28 | 27 | 29 | 35 | 40 | 35 |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 41 | 35 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 | 175 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 | 483 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | 25% | |
| Net Profit | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | 362 |
| EPS in Rs | 8.16 | 16.48 | 17.12 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 1,117% | 676% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 24% | 22% | 18% | ||
| Compounded Profit Growth | % | 42% | 227% | 51% | ||
| Stock Price CAGR | % | % | % | 81% | ||
| Return on Equity | % | 9% | 13% | 15% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 |
| Borrowings | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 |
| Other Liabilities | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 841 |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 |
| Fixed Assets | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 |
| Other Assets | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,477 |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 129 | 116 | -36 | 105 | 219 | 263 | 314 | 509 |
| Cash from Investing Activity | -158 | -262 | -260 | -102 | -99 | -191 | -536 | -395 |
| Cash from Financing Activity | 268 | -4 | 296 | 72 | -201 | -95 | 301 | -124 |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | -9 |
| Free Cash Flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | -83 |
| CFO/OP | 90% | 81% | -13% | 90% | 132% | 96% | 82% | 86% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 | 62 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 | 97 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 | 182 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 | -24 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 70 |
| ROCE % | 13% | 9% | 3% | 6% | 11% | 14% | 20% |
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 35.23% | 35.16% | 35.15% | 34.95% | 34.70% | 34.61% | 34.53% |
| FIIs | 11.72% | 12.36% | 14.57% | 22.50% | 21.41% | 21.17% | 19.65% |
| DIIs | 11.95% | 13.26% | 21.64% | 29.92% | 31.41% | 31.54% | 32.71% |
| Public | 41.08% | 39.21% | 28.64% | 12.65% | 12.49% | 12.69% | 13.11% |
| No. of Shareholders | 1,81,122 | 1,40,677 | 1,26,380 | 1,19,705 | 1,14,820 | 1,17,527 | 1,25,096 |
Fundamentals
Market Cap₹ 33,135 Cr.
Current Price₹ 1,560
Stock P/E90.1
Book Value₹ 117
ROCE19.6 %
ROE15.4 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)18%
Compounded Profit Growth (TTM)51%
Consolidated figures.
Valuation
Market capRs 32,738 Cr
Enterprise valueRs 33,507 Cr
P/E (TTM)90.50x
Price to book33.59x
Price to sales14.55x
EV / EBITDA48.35x
EV / EBIT64.69x
EV / sales14.89x
Price to cash flow124.44x
Earnings yield1.10%
Profitability
Operating margin (excl. other income)19.60%
Operating margin (incl. other income)21.58%
EBITDA margin30.80%
Pre-tax margin21.48%
Net profit margin16.08%
Net margin, latest quarter13.22%
ROE8.89%
ROCE10.57%
ROA3.73%
ROE, 3-year average3.58%
ROCE, 3-year average6.77%
ROA, 3-year average1.50%
ROE, 5-year average5.64%
ROCE, 5-year average8.37%
ROA, 5-year average2.82%
ROIC (approx.)22.51%
Tax rate24.20%
Other income / net worth2.98%
Growth
Sales growth (latest year)20.38%
Profit growth (latest year)728.93%
Sales CAGR, 3 years24.46%
Sales CAGR, 5 years16.08%
Profit CAGR, 3 years10.67%
Profit CAGR, 5 years2.42%
Sales growth QoQ-7.95%
Profit growth QoQ-29.69%
Sales growth YoY (latest quarter)11.66%
Profit growth YoY (latest quarter)21.22%
Per share
EPS (TTM)Rs 17.03
EPS (latest year)Rs 46.88
EPS (latest quarter)Rs 3.45
EPS, 3-year averageRs 18.67
EPS, 5-year averageRs 27.53
Book value per shareRs 45.89
Sales per shareRs 105.94
Cash flow per shareRs 12.39
Free cash flow per shareRs -3.91
Dividend per share, 3-year averageRs 38.45
Dividend per share, 5-year averageRs 38.45
Dividends
Dividend payout, 3-year average896.55%
Dividend payout, 5-year average896.55%
Efficiency
Asset turnover0.65x
Fixed asset turnover1.24x
Inventory turnover6.68x
Inventory days55 days
Debtor days64 days
Debtors turnover5.72x
Creditor days182 days
Cash conversion cycle-24 days
Working capital days70 days
Leverage
Total debtRs 928 Cr
Cash and bankRs 159 Cr
Net debtRs 769 Cr
Debt to equity0.95x
Net debt / EBITDA1.11x
Interest coverage15.00x
Current ratio (filing 2026-03-31)1.69x
Quick ratio (filing 2026-03-31)1.51x
Trade payables (filing 2026-03-31)Rs 285 Cr
Owners' fund to total sources43.09%
Debt to assets41.03%
Cash flow
Cash from Operating Activity (latest year)Rs 263 Cr
Cash from Investing Activity (latest year)Rs -191 Cr
Cash from Financing Activity (latest year)Rs -95 Cr
Net Cash Flow (latest year)Rs -24 Cr
Free cash flow (latest year)Rs -83 Cr
FCFE (approx.: FCF + change in debt)Rs -88 Cr
Cash from ops / profit, 5 years2.28x
Sales to cash flow5.57x
Statement figures
Net sales (TTM)Rs 2,250 Cr
Net sales (latest year)Rs 1,465 Cr
Sales (latest quarter)Rs 554 Cr
Operating profit excl. other income (latest year)Rs 287 Cr
Operating profit (latest quarter)Rs 148 Cr
Other income (TTM)Rs 35 Cr
EBITDA (TTM)Rs 693 Cr
PBDT (TTM)Rs 658 Cr
Profit before tax (TTM)Rs 483 Cr
Tax (latest year)Rs 26 Cr
Net profit (TTM)Rs 362 Cr
Net profit (latest year)Rs 83 Cr
Net profit (latest quarter)Rs 73 Cr
Depreciation (TTM)Rs 175 Cr
Depreciation (latest quarter)Rs 46 Cr
Interest (TTM)Rs 35 Cr
Cost of goods sold (latest year)Rs 584 Cr
Total expenditure (latest year)Rs 1,178 Cr
Total income (latest year)Rs 1,494 Cr
Share capitalRs 18 Cr
ReservesRs 957 Cr
Shareholders' fundsRs 975 Cr
Total assetsRs 2,262 Cr
Net blockRs 1,180 Cr
Capital work in progressRs 107 Cr
InvestmentsRs 2 Cr
ReceivablesRs 256 Cr
InventoryRs 87 Cr
Other liabilitiesRs 359 Cr
Shares outstanding (crore)21.24
Ownership
Promoter holding34.53% (-0.62 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SAILIFE | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.4% | -2.8% | -0.6 pts |
| 1 month | +1.5% | -6.8% | +8.3 pts |
| 3 months | +22.6% | -7.6% | +30.2 pts |
| 6 months | +58.6% | +0.4% | +58.2 pts |
| 1 year | +74.8% | -9.9% | +84.7 pts |
152 mutual fund schemes hold about ₹9,356 Cr.
Over three months 15 bought more and 120 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Nippon India Small Cap Fund | 1.16% | 958 | -8% |
| Invesco India Smallcap Fund | 5.04% | 794 | -16% |
| Invesco India Large & Mid Cap Fund | 5.05% | 593 | -13% |
| Nippon India Multi Cap Fund | 1.03% | 579 | +4% |
| Axis Small Cap Fund | 1.75% | 550 | -10% |
| Invesco India Midcap Fund | 3.14% | 499 | -17% |
| HSBC Small Cap Fund | 2.05% | 392 | -10% |
| Nippon India Pharma Fund | 3.94% | 373 | -8% |
| DSP Healthcare Fund | 7.45% | 286 | -12% |
| Aditya Birla SL Small Cap Fund | 2.96% | 184 | -15% |
| Axis Flexi Cap Fund | 1.17% | 164 | -8% |
| Axis Flexi Cap Fund | 1.17% | 158 | -8% |
| SBI Healthcare Opp Fund | 2.52% | 146 | -17% |
| Invesco India Flexi Cap Fund | 2.54% | 145 | -22% |
| Aditya Birla SL Flexi Cap Fund | 0.49% | 142 | -4% |
| Axis Multicap Fund | 1.25% | 137 | +21% |
| Aditya Birla SL Multi-Cap Fund | 1.74% | 131 | -10% |
| Invesco India Multicap Fund | 2.77% | 125 | -17% |
| HSBC Multi Cap Fund | 1.99% | 120 | -12% |
| Mirae Asset Healthcare Fund | 3.30% | 117 | -17% |
| PGIM India Midcap Fund | 1.04% | 117 | -6% |
| Aditya Birla SL ELSS Tax Saver Fund | 0.69% | 101 | -4% |
| Aditya Birla SL Midcap Fund | 1.45% | 101 | -8% |
| HDFC Multi Cap Fund | 0.48% | 100 | -6% |
| Aditya Birla SL Midcap Fund | 1.45% | 98 | -8% |
Red flags
F-score 8 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Insider trades
NSE insider and takeover-code disclosures| Date | Who | Role | Side | Shares | Value | How |
|---|---|---|---|---|---|---|
| 2025-02-21 | TUNER GHOSH | - | sell | 71,116 | Rs 5.07 Cr | Market Sale |
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.
Latest quarter
Jun 2026Sales ₹554 Cr +11.7% vs Jun 2025.
Net profit ₹73 Cr +21.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Sai Life Sciences Ltd?
Sai Life Sciences Ltd (SAILIFE) has a market capitalisation of Rs 33,135 Cr. at the 2026-10-01 close.
What is the P/E ratio of Sai Life Sciences Ltd?
Sai Life Sciences Ltd trades at a P/E of 90.1 on trailing twelve-month profit, at the 2026-10-01 close.
What were Sai Life Sciences Ltd's latest quarterly results?
In the Jun 2026 quarter, Sai Life Sciences Ltd sales was Rs 554 Cr (+11.7% vs Jun 2025) and net profit was Rs 73 Cr.
What is the 52-week high and low of Sai Life Sciences Ltd?
The 52-week high is Rs 1,697.00 and the 52-week low is Rs 783.85.